Navigation Links
Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
Date:8/6/2008

SAN DIEGO, Aug. 6 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., an acute care specialty pharmaceutical company, today announced the addition of a key senior executive to the company's management team. James S. Scibetta, joins Pacira as the Chief Financial Officer. Mr. Scibetta brings more than 20 years of financial leadership experience in private and public companies as well as investment banking to Pacira. Most recently he has been consulting to Genzyme Corporation following his instrumental role as CFO of Bioenvision Inc. in its 2007 sale to Genzyme for $345 million. Prior to his tenure at Bioenvision Mr. Scibetta was EVP and CFO of Merrimack Pharmaceuticals, Inc. where he aided the company in raising over $140 million of equity and debt capital. Mr. Scibetta is a Member of the Board of Directors and Chairman of the Audit Committee of both Labopharm Inc. and Nephros Inc. Prior to his life science company executive tenures, Jim held senior investment banking positions at PaineWebber and Shattuck Hammond Partners where he was responsible for sourcing and executing capital raising, strategic advisory and mergers & acquisitions transactions for a broad base of public and private technology-based healthcare companies encompassing businesses of biotechnology, pharmacy benefits management, CRO, health and wellness benefits management, disease management, evidenced-based medicine and others.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070618/PACIRALOGO)

Pacira President and CEO Dave Stack stated, "Jim brings outstanding experience and financial leadership with a strategic perspective focused on value creation to Pacira. We expect his contributions to enhance our organizational management, growth, and capital markets strategic initiatives."

About Pacira

Pacira is an acute care specialty pharmaceutical company with a primary focus on developing products which satisfy the needs of our customers in the institutional marketplace. The Company utilizes DepoFoam(R) delivery technology to cost-effectively improve patient care through enhanced dosing and administration profiles. Currently, the Company is developing DepoBupivacaine(TM) in phase III clinical studies for postsurgical pain. Revenues are generated from two approved products which are marketed by partners: DepoCyt(R) for lymphomatous meningitis and DepoDur(R) for post-surgical pain. Additional information about Pacira is available at http://www.pacira.com.

This press release contains forward looking statements, which involve risks and uncertainties within the meaning of the Private Securities Litigation Reform Act of 1995. There can be no assurance that actual results will not differ materially from the forward looking statements discussed in this press release. These forward looking statements include risks and uncertainties that current or future collaboration will prove to be commercially successful.

Contact: Taunia Markvicka

908-930-4995


'/>"/>
SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Flynn Pharma Acquires Rights From Pacira Pharmaceuticals to DepoDur(R), the Only Extended-Release Epidural Opioid for Post-Operative Pain, in Europe
2. Pacira Pharmaceuticals Names David M. Stack CEO and President
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
6. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
7. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
8. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
9. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
10. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
11. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... ... My T Chai, a South African company that creates a number of ... a popular website specializing in sales of nutritional products. , Chai tea is ... It spread across Asia and Africa quickly, and today recipes vary from region to ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... expected to be diagnosed globally; approximately 25,000 of them will be malignant.(1) As ... use of this type of healthcare model in the diagnosis and treatment of ...
(Date:4/24/2017)... , ... April 24, 2017 , ... As a former ... a thousand words. The good news for single women is that she put all ... is available on April 25th. Joan's insight, personal experiences and sparkling sense of humor ...
(Date:4/24/2017)... ... April 24, 2017 , ... A new global study of ... student well-being has seriously declined. "When disenfranchised youth from the heart of our ... State to turn the historic multi-ethnic and multi-religious powerhouses of the Middle East ...
(Date:4/24/2017)... ... April 24, 2017 , ... Miami ... attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue Regeneration and Implant ... will present its annual Global Symposium at the Fontainebleau Hotel located in Miami ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... release financial results for the first quarter 2017 after ... The Company,s management team will host a corresponding conference ... ET. Investors interested in listening to the ... for domestic callers or (703) 326-3030 for international callers, ...
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt ... the first patients in Nashville , ... the Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) ... designed to provide long-term reflux control by restoring normal ... affects nearly 65 million people in the ...
(Date:4/19/2017)... -- Companion animal vaccines are ... such as canine, avian and feline. ... as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, ... Vaccines. Attenuated live vaccines are derived from disease-causing ... been weakend under laboratory conditions. Conjugate vaccines are ...
Breaking Medicine Technology: